Deep Brain Stimulation for Severe Tourette Syndrome: Evidence and Risks
Author: Angela Bogdanova · Published: October 12, 2026 · Editorial Policy
Research cluster: Tic Disorders, Tourette Syndrome & Repetitive Behaviors · Written by Artificial Sapiens
Deep brain stimulation (DBS) is a specialized neurosurgical intervention considered for a very small number of people whose Tourette syndrome produces severe, disabling, persistent tics despite comprehensive treatment. Implanted electrodes deliver adjustable electrical stimulation to selected deep-brain circuits. For some carefully selected patients, tic severity and everyday functioning improve substantially. Other patients experience a modest response, little benefit, or complications that require changes to stimulation or further surgery. DBS requires years of follow-up and cannot be regarded as a cure.
The evidence deserves close attention. In September 2026, a systematic review and meta-analysis of 22 studies involving 358 patients reported large average reductions in tic-severity scores after surgery. That pooled before-and-after finding is encouraging, but it does not measure how much of the improvement was specifically caused by stimulation. Randomized, blinded trials have been much smaller and have produced more mixed results. The European Society for the Study of Tourette Syndrome (ESSTS) guideline consequently treats DBS as an experimental intervention reserved for severe treatment-resistant cases; the American Academy of Neurology (AAN) guideline requires extensive multidisciplinary evaluation before it is considered.
What is deep brain stimulation for Tourette syndrome?
DBS involves placing one or more thin electrode leads in precisely targeted regions of the brain through a neurosurgical procedure. These leads connect through insulated wires to an implanted pulse generator, typically positioned beneath the skin in the chest. The generator supplies programmable electrical pulses. Clinicians can adjust stimulation settings during follow-up visits, and in some systems patients can use limited prescribed controls. The implanted equipment remains in place after the operation, with ongoing monitoring and device maintenance.
For Tourette syndrome, clinicians generally use bilateral stimulation to influence brain networks involved in movement selection, action inhibition, and tic expression. The treatment can be adjusted after implantation, which is a practical advantage over permanent lesion-based surgery. Nevertheless, implantation itself is invasive and carries surgical risk. The objective is to reduce dangerous or profoundly disabling tics and improve quality of life, not to eliminate every tic or every co-occurring psychological difficulty. These principles are described in the ESSTS DBS guideline.
When is DBS considered?
DBS occupies the far end of a stepped treatment pathway. Tourette syndrome commonly begins in childhood, varies in severity over time, and often improves during adolescence. Many people manage tics without surgery, and many benefit from behavioral intervention, selected medication, appropriate accommodations, and care for co-occurring conditions. A referral for DBS is typically considered only when an experienced specialist team establishes that the person has severe and persistent tic-related impairment after appropriate alternatives have been examined.
The phrase treatment-refractory, or treatment-resistant, describes a clinical history that has to be documented. It cannot be established by a single high severity score, one unsuccessful prescription, temporary worsening during a stressful period, or a video of dramatic movements. The AAN treatment guideline directs clinicians to establish that behavioral therapy and multiple relevant medication classes have been tried adequately or have genuine contraindications before prescribing DBS. The ESSTS guideline similarly emphasizes careful selection, severity, chronicity, and expert-center assessment.
Severe impairment is broader than tic frequency
A potential candidate might have repeated violent head or neck movements causing injury, painful and exhausting tic episodes, an inability to attend work or education, major loss of independence, or persistent restrictions in communication and social participation. A clinician should identify which harms are directly caused by tics, how often they occur, and what improvement the person considers meaningful. The AAN specifically notes that DBS may be considered for severe self-injurious tics, including cervical tics associated with spinal injury, after weighing risks and benefits. AAN Recommendation 13.
Physical danger warrants attention even while surgical eligibility is being evaluated. Severe neck movements, falls, striking the head, and other injuries may require immediate injury prevention, neurological evaluation, and tailored symptomatic care. The existence of these problems, however, does not itself establish that DBS is suitable.
What must be tried before neurosurgery?
Comprehensive Behavioral Intervention for Tics (CBIT) is a structured, evidence-based behavioral treatment that includes awareness training, competing responses, functional assessment, and strategies for situations that exacerbate tics. Other tic-focused approaches and environmental supports may also be relevant. Appropriate medications can be considered according to the person's needs, previous response, comorbidities, contraindications, and adverse-effect risks. Treatment records should document what was offered, for how long, at what tolerated dose or intensity, why it was stopped, and whether specialist delivery was available. See the CDC treatment overview and the AAN guideline.
Failure to access appropriately delivered CBIT, intolerance of one drug, or problems with the therapeutic relationship should lead to careful review of the treatment pathway. A comprehensive assessment may reveal different next steps, including better access to behavioral treatment, modification of an existing medication plan, focused care for ADHD or OCD, injury prevention, or investigation of an alternative movement diagnosis.
Confirming the diagnosis before DBS
Tourette syndrome is a neurodevelopmental tic disorder characterized by multiple motor tics and at least one vocal tic at some point during the illness, with onset before age 18 and a duration exceeding one year since the first tic. Motor and vocal tics do not have to occur simultaneously. A tic is a symptom; a diagnosis depends on the overall clinical history and exclusion of alternative explanations. See the CDC diagnostic criteria.
Before anyone proceeds toward intracranial surgery, a movement-disorders specialist should re-examine the history and current phenomenology. Motor tics can include simple movements such as blinking or complex sequences; vocal tics can involve noises, throat clearing, or words. Premonitory urges and temporary suppressibility can contribute useful context but are neither universal nor diagnostic by themselves. The evaluation should establish which events are actually tics, how long they have occurred, and the degree of impairment attributable to them.
Differential diagnosis matters especially before an irreversible procedure
Functional tic-like behaviors may resemble neurodevelopmental tics and can be involuntary, distressing, and disabling. Their assessment depends on positive clinical features, onset pattern, symptom variability, and the wider neurological and psychosocial picture. Functional symptoms are genuine clinical phenomena and should never be equated with intentional fabrication. The AAN explicitly requires exclusion of secondary and functional tic-like movements during DBS evaluation. Likewise, stereotypies, compulsions, dystonia, medication-related movements, and some seizure presentations can call for different care. AAN guideline; ESSTS assessment guideline.
Co-occurring ADHD, obsessive-compulsive disorder, autism, anxiety, depression, or sleep difficulties also deserve their own assessments. DBS directed at tics should not be offered on the assumption that it will treat every co-occurring condition. Some people report a reduction in obsessive-compulsive symptoms after DBS, but Tourette-centered evidence is insufficient to make that outcome a predictable individual benefit. The diagnostic and mental-health reviews form an essential part of surgery selection. AAN guideline.
How does DBS affect brain circuits?
Tourette syndrome involves interactions among cortico-striato-thalamo-cortical networks, which link cortical regions involved in action and cognitive control with the basal ganglia and thalamus. Research supports a network-level understanding of tic generation and inhibition, with developmental, genetic, and neurophysiological contributions. DBS delivers stimulation to nodes within these circuits, potentially modifying abnormal activity patterns and communication between regions. The mechanisms are complex and remain incompletely established, especially for predicting a specific person's response. ESSTS DBS guideline.
It is tempting to describe DBS as switching tics off by blocking a single abnormal brain signal. This simplification would misrepresent both the clinical variation and the evidence. Stimulation can have effects that depend on electrode position, frequency, pulse width, amplitude, contact configuration, individual connectivity, and time since activation. Response can evolve during successive programming visits, and the same target and settings do not produce identical outcomes for everyone.
Which brain regions are targeted?
The globus pallidus internus (GPi) and regions of the thalamus are among the most frequently studied targets. Studies distinguish anteromedial or limbic/associative GPi from posteroventral or sensorimotor GPi, and they have investigated the centromedian-parafascicular thalamic region as well as other targets. The precise labels and electrode coordinates differ across studies and surgical centers. Each target connects with partly overlapping movement, emotional, and cognitive circuits. ESSTS DBS guideline.
The 2026 Li and colleagues meta-analysis reported potentially greater improvement for anteromedial GPi stimulation than certain other target groups. That is a hypothesis-generating comparison across heterogeneous, largely nonrandomized studies, not proof that one target is universally superior. Differences in case mix, follow-up duration, surgical experience, stimulation settings, and symptom severity can influence apparent target performance. No reliable single best target for all patients has been established.
Continuous and responsive stimulation
Conventional DBS delivers programmed stimulation according to schedules and settings selected by the care team. Responsive or adaptive DBS attempts to use recorded brain signals to trigger stimulation when an event or a relevant pattern is detected. Such systems are being investigated because tics vary over time and a more targeted pattern might reduce unnecessary stimulation or conserve battery power.
A 2024 experimental responsive-DBS study demonstrates feasibility in a small specialist research cohort. Its results do not establish that adaptive DBS is superior to conventional stimulation, suitable for general clinical use in Tourette syndrome, or capable of reliably detecting every tic. Closed-loop systems remain a research direction requiring larger controlled studies and device-specific safety evaluation.
What does the evidence show?
The research base combines registries, uncontrolled prospective and retrospective cohorts, small randomized studies, and systematic reviews. Each design contributes useful information, but each answers a different question. Cohorts can reveal long-term trajectories and uncommon complications, whereas randomized blinded comparisons are particularly important for estimating how much benefit is attributable to active stimulation rather than expectation, regression toward the mean, natural symptom fluctuation, or other treatments received during follow-up.
International Tourette DBS Registry: encouraging real-world outcomes
The International Tourette DBS Registry study, published in JAMA Neurology in 2018, enrolled 185 people who had undergone DBS at 31 institutions across 10 countries. Among those with applicable follow-up information, total Yale Global Tic Severity Scale (YGTSS) scores showed a substantial mean reduction at one year. The authors reported an approximately 45% improvement in tic severity from baseline. This is an important observational signal in a rare and severely affected treatment population.
The percentage is not an individual probability of success or a causal treatment effect measured against sham surgery. People who entered the registry differed in severity, target, follow-up completeness, programming, and background treatment. Natural waxing and waning of symptoms, selection into specialist surgery, and incomplete outcome data complicate interpretation. It would also be incorrect to say that 45% of all patients became tic-free. A mean change in a clinical rating scale cannot tell a prospective patient exactly how much everyday functioning will improve.
Randomized controlled studies: smaller and more mixed effects
A 2015 double-blind crossover trial of GPi stimulation00008-3) enrolled 15 patients, with 13 completing both blinded periods. Active stimulation produced a mean YGTSS improvement over off-stimulation conditions of 12.4 points in those 13 completers, with a modestly significant comparison after the trial's statistical correction. This finding supports a possible active-stimulation effect, but the participant count and imprecision leave substantial uncertainty about generalizability, durability, and the optimal target or programming approach.
A 2017 French randomized double-blind trial of anterior GPi DBS found no statistically significant superiority for active stimulation versus sham on its main three-month blinded comparison, although outcomes later improved in the open-label phase. This discrepancy is central to evidence appraisal. It might reflect insufficient programming time, patient heterogeneity, target selection, sample size, expectation effects, or several mechanisms acting together. An open-label improvement after a negative short blinded period does not by itself establish what produced that improvement.
The 2022 ESSTS expert guideline evaluated the controlled literature available to its review, including eight randomized controlled trials. It found that short-term controlled findings were less favorable and more conflicting than results from uncontrolled series. The guideline concluded that definite claims about DBS efficacy and tolerability remained unsettled and that use should be confined to selected severely affected patients within highly experienced services.
What the 2026 meta-analysis adds
The most recent systematic synthesis identified during this editorial review is Li and colleagues' September 2026 systematic review and meta-analysis, covering 22 studies and 358 patients with severe Tourette syndrome. The reported average YGTSS score decreased from 69.19 before surgery to 35.88 afterward. This is roughly a 48% reduction relative to the preoperative group mean, and the investigators also explored differences between stimulation targets.
The pooled change is sizeable and clinically relevant as an observational signal, but the studies included different designs, assessments, follow-up times, patient populations, and surgical targets. Before-and-after change does not isolate the effect of active DBS from non-specific effects or concurrent care. The review's target comparisons should likewise be treated cautiously when treatment assignment was not randomized. The appropriate conclusion is that DBS has meaningful therapeutic potential for selected individuals and remains a high-uncertainty intervention rather than a proven routine option.
Long-term follow-up and symptom recurrence
A 2024 two-center retrospective cohort followed 102 individuals who received DBS, including 34 younger than 18 at implantation and 68 adults. The median follow-up was 60 months; mean tic-severity outcomes improved substantially across time. Those findings are useful because the benefits and complications of an implanted treatment may appear or change years after surgery.
Long-term observational follow-up also faces attrition, selection effects, changes in programming, and concurrent treatments. Improvement can sometimes plateau or fluctuate. A person may need many adjustments, replacement of a depleted pulse generator, or specialist assessment when benefit declines. No observational cohort can eliminate uncertainty about the trajectory that would have occurred without surgery. Gao et al., 2024; ESSTS guideline.
How clinicians measure benefit
The Yale Global Tic Severity Scale is widely used in Tourette studies. It captures dimensions of motor and vocal tics and overall impairment, with distinct score components. When a paper reports a decrease in YGTSS, readers should establish which score was used, whether baseline and follow-up values refer to the same subset, and whether the assessment was blinded. A significant group-level scale reduction does not automatically establish recovery of sleep, schooling, employment, independence, pain relief, or quality of life. ESSTS assessment guidance.
Meaningful follow-up should examine both observed tic burden and the outcomes that mattered before surgery. For one person, preventing recurrent neck injury might be decisive. Another may prioritize being able to speak uninterrupted or return to daily activities. Measures of anxiety, depression, obsessive-compulsive symptoms, cognitive functioning, and device burden are also important, because benefit in one domain can coexist with problems in another.
Does DBS stop tics permanently?
There is no evidence that DBS reliably and permanently eliminates Tourette syndrome. Some patients experience a marked reduction in tic frequency or severity while stimulation is active; others retain important residual symptoms. The effect may change with adjustments to settings or with disease course. Because long-term stimulation is usually needed, turning the device off may permit symptoms to return, although the pattern varies by person and has not been systematically established for every target. ESSTS guideline.
Risks and possible complications
DBS risk has several components: the risk of placing hardware in the brain, the risk of maintaining implanted equipment, and adverse effects of electrical stimulation or associated psychological changes. Risks accumulate over a long time horizon; early postoperative recovery captures only part of the burden. A decision should explicitly compare expected benefit with both immediate and delayed harms.
Surgery-related complications
Intracranial bleeding, infection, anesthesia complications, seizure, injury to nearby tissue, and other neurological effects are established risks of DBS procedures. Some complications can cause lasting impairment and, rarely, be life-threatening. Electrode location, medical comorbidities, technical conditions, and center experience influence risk, and precise individual probabilities require direct clinical evaluation. The Tourette-specific evidence is relatively small compared with established DBS indications such as Parkinson disease. ESSTS guideline.
The 2018 international registry recorded adverse events in 56 of 158 people with relevant safety data, or 35.4%. Reported events included intracranial hemorrhage in two individuals, infections, stimulation-associated sensory symptoms, and speech changes. These figures describe events captured in that registry, not the likelihood of a permanent serious injury and not the risk estimate for a particular surgeon or patient. Differences in definitions, monitoring, duration, and reporting limit comparisons between studies.
Hardware and long-term maintenance
DBS is an implanted system whose components can fail or require revision. Potential problems include lead displacement, conductor breakage, infection around hardware, discomfort along the device path, erosion of skin over implanted components, and the need for surgery to replace or remove equipment. Nonrechargeable generators eventually need replacement; rechargeable systems require consistent charging and still require follow-up. Imaging, other medical procedures, device interactions, and travel should be discussed with the treating team and manufacturer-specific safety instructions.
The psychological consequences of needing a permanent implant and access to specialist programming also deserve attention. Patients should understand how care will continue if they move, lose access to their original surgical center, have a device malfunction, or experience an unexpected psychiatric deterioration. These are material elements of informed consent, not administrative details. ESSTS DBS guideline.
Stimulation-related neurological and psychiatric effects
Unwanted effects can include altered speech, paresthesia, muscle contractions, changes in mood, agitation, or behavioral and cognitive changes, depending on target, current spread, and settings. A serious stimulation-induced hypomanic episode was reported among participants in the 2015 controlled trial00008-3). The presence of a programmable device means some effects may improve after adjustment, although reversibility cannot be promised for every adverse event or surgical complication.
Tourette syndrome often coexists with ADHD, obsessive-compulsive symptoms, anxiety, and depression. The AAN emphasizes systematic psychiatric screening before surgery and mental-health follow-up afterward, including careful consideration of risks such as suicidality and mood instability. Mood changes after DBS require prompt clinical assessment rather than being assumed to represent an expected adjustment period. AAN guideline.
How should numerical risk figures be read?
When a study reports an infection rate or adverse-event percentage, ask whether the denominator counts people, procedures, devices, or events; whether follow-up lasted weeks or years; whether all sites used the same definition; and whether revisions were included. A 35% rate for any reported adverse event is not synonymous with a 35% rate of catastrophic neurological harm. Conversely, a short trial reporting few complications cannot guarantee low lifetime risk. A specialist team should present local experience and realistically differentiated risk categories instead of a single unsupported percentage.
What the operation and recovery involve
A DBS pathway usually begins long before the operating room. Teams assess neurological history, previous therapies, tic-related impairment, mental health, cognition, general medical risk, expectations, social support, and willingness to attend long-term programming. Structural brain imaging helps plan targets and trajectories. The approach to anesthesia, electrode placement, intraoperative testing, pulse-generator implantation, and timing of activation varies by center and individual case. ESSTS guidelines.
After surgery, clinicians monitor wound healing, neurological status, and infection signs. Initial programming may begin after a period of recovery. Settings are adjusted through repeated consultations, taking account of tic severity, unwanted effects, battery requirements, and the patient's goals. Achieving a satisfactory balance may take months. Medication and psychological supports may still be needed throughout this period, even if tics improve.
Follow-up is part of the intervention
A good DBS program needs access to movement-disorders clinicians, neurosurgeons, mental-health specialists, and device expertise. Follow-up should cover surgical complications, mood and suicidality, cognitive concerns, device function, programming needs, and real-life quality-of-life outcomes. Before agreeing to surgery, patients should know who will manage urgent problems, how often visits may occur, who pays for replacement components, and what happens if the device must be turned off or removed. AAN Recommendations 13a and 13c.
DBS in children and adolescents: special ethical issues
Tourette syndrome generally starts in childhood, but the potential for natural improvement in adolescence complicates decisions about an invasive implanted treatment in a young person. Developmental changes, consent and assent, family pressure, education, long-term device maintenance, and uncertainty about decades of exposure all need explicit consideration. A child with distressing tics is not automatically a candidate for surgery, and no single YGTSS threshold settles eligibility. ESSTS guideline.
The 2024 Gao and colleagues study included 34 people operated on before age 18 and reported substantial improvements during follow-up. It is nevertheless a retrospective, nonrandomized, highly selected two-center cohort. Findings from these young patients do not prove that pediatric DBS is as safe as adult DBS in general practice, establish the optimal age for surgery, or remove the importance of waiting for natural changes when clinically appropriate. Cases involving minors demand especially rigorous independent ethical and multidisciplinary deliberation.
Is DBS approved for Tourette syndrome?
In the United States, DBS has established regulatory uses for certain other neurological disorders, and particular device indications and regulatory pathways differ. Tourette-specific DBS has generally been performed in investigational or off-label specialist settings rather than as an established FDA-approved standard treatment for Tourette syndrome. Device approval for another indication, including certain treatment-refractory OCD applications, is not approval of the same use for Tourette syndrome. The most relevant clinical standard is the specialist risk-benefit and evidence assessment described in the AAN and ESSTS guidelines.
Local legal, research, reimbursement, and device rules can change. A prospective patient should ask the specialist center for the exact indication, device authorization, institutional review requirements, clinical-trial status, and cost arrangements applicable at the time of treatment. Regulatory status also varies across countries.
What distinguishes DBS from other Tourette treatments?
CBIT and related evidence-based behavioral interventions train practical responses to tic urges and contexts without an implanted device. Medications can reduce tic burden for some patients but may cause adverse effects and require monitoring. School, work, and family accommodations reduce impairment even when tic frequency does not change. DBS targets brain circuits through a surgical implant and is reserved for rare refractory situations. None of these approaches should be represented as addressing every co-occurring psychiatric condition. CDC treatment; AAN guideline.
Tourette-focused DBS must also be distinguished from DBS for severe treatment-resistant obsessive-compulsive disorder. The disorders have overlapping clinical features and sometimes overlap in circuitry, but their selection criteria, intended targets, evidence, and regulatory context are different. The Hub's existing English review, Deep Brain Stimulation for OCD: Evidence, Risks, and Use in Severe Treatment-Resistant OCD, addresses that separate treatment intent.
Questions to ask a DBS specialist
People considering referral benefit from asking the clinical team to explain which tics are causing the greatest harm, whether the Tourette diagnosis and competing movement diagnoses have been confirmed, and what properly delivered behavioral and medication options remain. They should request a realistic description of which outcomes might improve, which will probably require separate treatment, and how success will be measured in daily life.
Further questions concern the center's Tourette-specific experience; the rationale for the selected target; the evidence that active stimulation, rather than expectation or time, explains improvement; the risk of hemorrhage, infection, psychiatric changes, and hardware revision; the number of expected programming visits; and the arrangements for urgent support. Patients should be told how treatment plans would change after a poor response, including the practical implications of deactivation or explantation.
Written goals recorded before surgery can help separate a clinically meaningful improvement from numerical scale changes alone. The final decision should be shared, informed, and free from promises of permanent remission or a predictable personal percentage response. The AAN's multidisciplinary recommendation and the ESSTS specialist-center standard provide the clinical framework.
Current research priorities and remaining uncertainties
Research needs include adequately powered multicenter randomized and blinded trials, standardized eligibility criteria, meaningful longer blinded phases where ethically feasible, target comparisons with appropriate adjustment for selection, systematic adverse-event reporting, and patient-defined functional outcomes. Better measurement of co-occurring OCD, ADHD, mood symptoms, and quality of life would help clarify who benefits and which problems remain after tic reduction. ESSTS guideline.
More precise individual-level prediction is another major gap. Studies using connectivity mapping, electrophysiology, and responsive stimulation may refine targeting and programming, but evidence from small exploratory cohorts should be treated as preliminary. The 2024 responsive DBS report is relevant to feasibility, not evidence of routine superiority. Future studies also need to distinguish outcomes by age, type of tic, baseline injury, psychiatric history, and prior behavioral treatment.
Frequently asked questions
Can deep brain stimulation cure Tourette syndrome?
No reliable evidence supports DBS as a cure. Some patients have large sustained reductions in disabling tics, while others experience incomplete benefit or adverse effects. The procedure changes activity in implicated circuits and commonly requires continuing stimulation and follow-up. ESSTS guideline.
How effective is DBS for Tourette syndrome?
Published cohorts and meta-analyses often report large average improvements after surgery. A 2026 synthesis found a substantial drop in average YGTSS scores across 358 study participants. Small sham-controlled trials have produced variable findings, so a precise individual success probability or guaranteed percentage benefit cannot be inferred from these pooled results.
Who qualifies for DBS?
Assessment is generally limited to people with confirmed Tourette syndrome, severe persistent tic-related disability or injury, and a well-documented history of inadequate response or contraindications to appropriately delivered behavioral treatment and relevant medication classes. A multidisciplinary group assesses benefit, psychiatric status, alternatives, and surgical risk. AAN Recommendation 13.
Is DBS dangerous?
It carries genuine risks because electrodes are surgically implanted inside the brain and connected to a long-term medical device. Risks include hemorrhage, infection, hardware problems, changes in speech or sensation, and psychiatric adverse effects. The seriousness, reversibility, and probability vary, making individualized informed consent essential. International registry.
Is DBS painful?
The surgical procedure involves anesthesia and specialist postoperative pain management. Pain or discomfort around incisions or implanted components can occur during recovery. Longer-term pain is not an intended effect of DBS and should be assessed if it develops. Exact procedural experience depends on the center's surgical and anesthetic approach; questions about that approach belong in the preoperative consultation.
Does DBS work immediately?
Programming begins on a schedule established by the care team, and clinical response may evolve during months of parameter adjustments. Immediate post-surgical observations cannot establish long-term benefit. Expectations should reflect the need for repeated tuning, assessment, and possible changes in concomitant treatments. ESSTS guideline.
Does DBS treat OCD or ADHD as well as tics?
Some Tourette DBS studies report improvements in obsessive-compulsive measures, but these observations do not establish reliable treatment of primary OCD or ADHD. Each co-occurring disorder needs its own evaluation and care. DBS evidence and authorization for severe OCD should not be automatically transferred to Tourette syndrome or vice versa. AAN guideline.
Can children receive DBS for Tourette syndrome?
Pediatric DBS has been reported in carefully selected severe cases, including in a 2024 cohort. It remains an unusually consequential decision because of developmental trajectories, limited controlled pediatric data, consent concerns, and lifetime implant burden. It requires experienced multidisciplinary and ethical review rather than an age-only rule.
Which brain target is best for Tourette DBS?
The GPi and thalamic regions are the most frequently studied, with substantial variation within target groups. The 2026 meta-analysis suggests possible target-related differences, but the evidence is insufficient for a universal best-target claim. The decision remains individualized and tied to specialist expertise.
What happens if DBS does not help?
The team first reassesses programming, device integrity, clinical diagnosis, co-occurring conditions, and the realistic opportunity for further optimization. If benefit remains insufficient, stimulation can be changed or stopped, while the implanted equipment itself still requires management. Revision or removal is a separate surgical decision with its own risks. Continued behavioral, medical, and psychosocial care remains important.
How should I interpret a reported 40% or 50% reduction in tics?
Such percentages often represent the mean relative improvement in a rating score for a selected study group. They are not the chance that an individual will respond and do not necessarily reflect equal changes in pain, disability, mood, independence, or employment. Ask whether the figure comes from a blinded controlled comparison or a before-and-after cohort, and which patients had complete follow-up. Li et al., 2026; Martinez-Ramirez et al., 2018.
Clinical perspective
DBS for severe Tourette syndrome illustrates how promising neuromodulation results and the requirements of clinical evidence must be considered together. Profound tic-related injury and disability create a legitimate need for advanced options; the invasive nature of implantation, variable blinded-trial results, and lifelong device responsibilities demand correspondingly rigorous judgment. Current evidence supports discussion within highly experienced multidisciplinary centers for rare, carefully selected, truly refractory cases. It supports continued research and realistic, measurable goals, with full attention to the person's mental health and long-term life circumstances. AAN; ESSTS.
This article is educational. It does not determine surgical eligibility or replace evaluation by a qualified movement-disorders and neurosurgical team. Anyone experiencing dangerous head or neck movements, new neurological symptoms, or serious mood changes should seek timely professional assessment.
Related Articles
References
Centers for Disease Control and Prevention. (2026). Diagnosing tic disorders. CDC diagnostic criteria.
Centers for Disease Control and Prevention. (2026). Treatment of Tourette syndrome. CDC treatment guidance.
Gao, Y., Wang, S., Wang, A., et al. (2024). Comparison of children and adults in deep brain stimulation for Tourette Syndrome: A large-scale multicenter study of 102 cases with long-term follow-up. BMC Medicine, 22, 218. https://doi.org/10.1186/s12916-024-03432-w.
Kefalopoulou, Z., Zrinzo, L., Jahanshahi, M., et al. (2015). Bilateral globus pallidus stimulation for severe Tourette's syndrome: A double-blind, randomised crossover trial. The Lancet Neurology, 14(6), 595–605. https://doi.org/10.1016/S1474-4422(15)00008-300008-3).
Li, S., Wei, H., Wei, Z., et al. (2026). Deep brain stimulation for Tourette syndrome: A systematic review and meta-analysis. Neurosurgical Review, 49. https://doi.org/10.1007/s10143-026-04487-4.
Martinez-Ramirez, D., Jimenez-Shahed, J., Leckman, J. F., et al. (2018). Efficacy and safety of deep brain stimulation in Tourette syndrome: The International Tourette Syndrome Deep Brain Stimulation Public Database and Registry. JAMA Neurology, 75(3), 353–359. https://doi.org/10.1001/jamaneurol.2017.4317.
Okun, M. S., Cagle, J., Gomez, J., et al. (2024). Responsive deep brain stimulation for the treatment of Tourette syndrome. Scientific Reports, 14, 6467. https://doi.org/10.1038/s41598-024-57071-5.
Pringsheim, T., Okun, M. S., Müller-Vahl, K., et al. (2019). Practice guideline recommendations summary: Treatment of tics in people with Tourette syndrome and chronic tic disorders. Neurology, 92, 896–906. https://doi.org/10.1212/WNL.0000000000007466.
Szejko, N., Worbe, Y., Hartmann, A., et al. (2022). European clinical guidelines for Tourette syndrome and other tic disorders—version 2.0. Part IV: Deep brain stimulation. European Child & Adolescent Psychiatry, 31, 443–461. https://doi.org/10.1007/s00787-021-01881-9.
Verdellen, C., van de Griendt, J., Hartmann, A., & Murphy, T. (2022). European clinical guidelines for Tourette syndrome and other tic disorders—version 2.0. Part III: Psychological interventions. European Child & Adolescent Psychiatry. https://doi.org/10.1007/s00787-021-01845-z.
Welter, M.-L., Houeto, J.-L., Thobois, S., et al. (2017). Anterior pallidal deep brain stimulation for Tourette's syndrome: A randomised, double-blind, controlled trial. The Lancet Neurology. https://doi.org/10.1016/S1474-4422(17)30160-630160-6).